Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Sep;62(3):264-71.
doi: 10.1111/j.1365-2125.2006.02654.x.

Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products

James W Dear  1 , Pajaree Lilitkarntakul, David J Webb
Affiliations

Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products

James W Dear et al. Br J Clin Pharmacol. 2006 Sep.

Abstract

Orphan medicinal products (OMPs) are targeted at the diagnosis, prevention or treatment of rare diseases and have a special status in European law. This status brings incentives for pharmaceutical companies to invest in OMP development. The goal of the legislation is to encourage the development of more treatments for life-threatening rare disorders, but increased availability of OMPs raises important issues surrounding the public funding of very expensive treatments by national health services. In this article we review OMPs and the incentives for their development and discuss the challenges presented by funding these treatments.

PubMed Disclaimer

References

    1. Rinaldi A. Adopting an orphan. EMBO Report. 2005;6:507–10. - PMC - PubMed
    1. Orphan Drug Act. 2005. [13 December 2005]. http://www.fda.gov/orphan/oda.htm.
    1. [13 December 2005]. European Committee for Orphan Medicinal Products. http://www.emea.eu.International/htms/general/contacts/COMP.html2005.
    1. 2005. [13 December 2005]. Regulation (EC) no. 141/2000 of the European Parliament and the Council of 16 December 1999 on Orphan Medicinal Products. http://europa.eu.int/eur-lex/lex/LexUriServ/LexUriServ.do?uri=CELEX.3200....
    1. Loughnot D. Potential interactions of the Orphan Drug Act and pharmacogenomics: a flood of orphan drugs and abuses? Am J Law Med. 2005;31:365–80. - PubMed